<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814294</url>
  </required_header>
  <id_info>
    <org_study_id>DP 01-2007-03</org_study_id>
    <nct_id>NCT00814294</nct_id>
  </id_info>
  <brief_title>Study of Two Doses of Oral HDV-Insulin and Placebo With Background Metformin Treatment in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>An 18-Week Randomized, Double-Blind, Multicenter, Comparator Study of Two Doses of Oral HDV-Insulin and Placebo With Background Metformin Treatment in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diasome Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diasome Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to compare the reduction in mean glycated hemoglobin&#xD;
      levels (HbA1c) between 2 doses of oral HDV-I and placebo in type 2 diabetic patients on&#xD;
      background metformin therapy at the end of 18 weeks of treatment.&#xD;
&#xD;
      The secondary objectives are:&#xD;
&#xD;
        -  To evaluate the effects of oral HDV-I versus placebo on the 7-point glucose test,&#xD;
           fasting plasma glucose (FPG), insulin, homeostasis model assessment of insulin&#xD;
           resistance (HOMA-IR), homeostasis model assessment of β-cell function (HOMA-β),&#xD;
           frequency of hypoglycemic events, body weight, and lipid levels; and&#xD;
&#xD;
        -  To evaluate the safety and tolerability of oral HDV-I.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled study with a&#xD;
      washout/stabilization period of up to 12 weeks in duration and an 18-week double-blind&#xD;
      treatment period. There will be a total of 8 visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this trial is to compare the reduction in mean glycated hemoglobin levels (HbA1c) between 2 doses of oral HDV-I and placebo in type 2 diabetic patients on background metformin therapy at the end of 18 weeks of treatment.</measure>
    <time_frame>18 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of oral HDV-I versus placebo on the 7-point glucose test</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of oral HDV-I versus placebo on fasting plasma glucose (FPG) and insulin</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of oral HDV-I versus placebo on the homeostasis model assessment of insulin resistance (HOMA-IR)and homeostasis model assessment of β-cell function (HOMA-β)</measure>
    <time_frame>18 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of oral HDV-I versus placebo on frequency of hypoglycemic events, body weight, and lipid levels</measure>
    <time_frame>18 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">239</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>1; Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive a sugar pill.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2; Oral Hepatic Directed Vesicles (HDV)-Insulin (U-5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Oral HDV-Insulin (U-5).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3; Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive Oral HDV-Insulin (U-15).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo capsule,0 units, quater in die (QID) for 18 weeks</description>
    <arm_group_label>1; Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15)</intervention_name>
    <description>Oral HDV-I Caps; 15 U; quater in die (QID) for 18 weeks.</description>
    <arm_group_label>3; Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Hepatic Directed Vesicles (HDV)-Insulin (U-5)</intervention_name>
    <description>Oral HDV-I; Caps; 5 U; quater in die (QID) for 18 weeks.</description>
    <arm_group_label>2; Oral Hepatic Directed Vesicles (HDV)-Insulin (U-5)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 to 70 years, inclusive;&#xD;
&#xD;
          -  Diagnosis of type 2 diabetes mellitus;&#xD;
&#xD;
          -  Fasting plasma glucose &lt;=250 mg/dL;&#xD;
&#xD;
          -  BMI &lt;=45 kg/m2;&#xD;
&#xD;
          -  HbA1c levels as follows at Screening:&#xD;
&#xD;
          -  On a stable dose of metformin monotherapy with an HbA1c &gt;=7.5% and &lt;=9.5%;&#xD;
&#xD;
          -  On metformin and 1 other OAD (excluding TZD, exenatide, or insulin) with an HbA1c&#xD;
             &gt;=6.8% and &lt;=9.0%;&#xD;
&#xD;
          -  Naïve to antidiabetic therapy or have not been on a stable dose of metformin&#xD;
             monotherapy for &lt;12 weeks with an HbA1c &gt;=8.0% and &lt;=10.5%;&#xD;
&#xD;
          -  Understanding of the study procedures and agreement to participate in the study,&#xD;
             giving written informed consent;&#xD;
&#xD;
          -  Women may be enrolled if all of the following criteria (in addition to the above&#xD;
             criteria) are met:&#xD;
&#xD;
          -  They are not pregnant (women of childbearing potential must have a negative serum&#xD;
             pregnancy test at Visit 1);&#xD;
&#xD;
          -  They are not breast-feeding;&#xD;
&#xD;
          -  They do not plan to become pregnant during the study; and&#xD;
&#xD;
          -  They have had a hysterectomy or tubal ligation 6 months prior to the study, have been&#xD;
             post-menopausal for 1 year, or will practice a method of birth control throughout the&#xD;
             study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of type 1 diabetes and/or history of ketoacidosis;&#xD;
&#xD;
          -  History of chronic (&gt;2 months) use of insulin therapy or recent initiation of insulin&#xD;
             use intended for chronic administration;&#xD;
&#xD;
          -  Use of TZD (pioglitazone or rosiglitazone) or exenatide within 3 months prior to&#xD;
             Screening;&#xD;
&#xD;
          -  Use of prescription or over the counter weight loss agents within 1 month prior to&#xD;
             Screening;&#xD;
&#xD;
          -  Use of any lipid-altering, antihypertensive, and other chronic use medication not&#xD;
             stable for 1 month prior to Screening;&#xD;
&#xD;
          -  Use of any medication that may alter blood glucose analyses;&#xD;
&#xD;
          -  Any serious disorder including cardiac, pulmonary, hepatic, uncontrolled&#xD;
             endocrine/metabolic, hematologic/oncologic (within the last 5 years), neurologic, and&#xD;
             psychiatric diseases that would interfere with the conduct of the study or&#xD;
             interpretation of the data;&#xD;
&#xD;
          -  Require regular use of medication that interferes with the oral absorption and/or&#xD;
             metabolism of insulin or metformin;&#xD;
&#xD;
          -  History of pancreatitis;&#xD;
&#xD;
          -  History of acquired immune deficiency syndrome or human immunodeficiency virus;&#xD;
&#xD;
          -  History of drug or alcohol abuse within the past 2 years;&#xD;
&#xD;
          -  Hospitalization for any cause within 14 days prior to the study;&#xD;
&#xD;
          -  History of an allergic or toxic response to oral HDV-I;&#xD;
&#xD;
          -  Uncontrolled hypertension: systolic blood pressure &gt;160 mmHg and diastolic blood&#xD;
             pressure &gt;95 mmHg;&#xD;
&#xD;
          -  Triglycerides &gt;400 mg/dL;&#xD;
&#xD;
          -  Aspartate aminotransferase or alanine aminotransferase &gt;2.5 times the upper limit of&#xD;
             normal (ULN);&#xD;
&#xD;
          -  Creatine phosphokinase &gt;3 times the ULN;&#xD;
&#xD;
          -  Patients on a weight loss program with ongoing weight loss, or starting an intensive&#xD;
             exercise program within 4 weeks of starting the study;&#xD;
&#xD;
          -  Use of any investigational drug within 30 days preceding the first dose of study&#xD;
             medication; or&#xD;
&#xD;
          -  Employment by the research center.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Len Rosenberg, PhD, RPh</last_name>
    <role>Study Director</role>
    <affiliation>Diasome Pharmaceuticals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Orloff, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medpace, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <zip>35661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Litchfield Park</city>
        <state>Arizona</state>
        <zip>85340</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Concord</city>
        <state>California</state>
        <zip>94520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paramount</city>
        <state>California</state>
        <zip>90723</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Mateo</city>
        <state>California</state>
        <zip>94401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valley Village</city>
        <state>California</state>
        <zip>91607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiefland</city>
        <state>Florida</state>
        <zip>32626</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <zip>42003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Picayune</city>
        <state>Mississippi</state>
        <zip>39466</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delaware</city>
        <state>Ohio</state>
        <zip>43015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <zip>43701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <zip>15009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <zip>78404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <zip>76054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odessa</city>
        <state>Texas</state>
        <zip>79761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manassas</city>
        <state>Virginia</state>
        <zip>20110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 23, 2008</study_first_submitted>
  <study_first_submitted_qc>December 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2008</study_first_posted>
  <disposition_first_submitted>May 3, 2021</disposition_first_submitted>
  <disposition_first_submitted_qc>May 3, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">May 6, 2021</disposition_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

